[Audio] Answer:Pneumococcal conjugate ( Measles AND Varicella are live vaccines contraindicated in patients with HIV whose CD4 is < 200 cells/uL. The pneumococcal conjugate vaccine and recombinant varicella zoster vaccine are the non-live vaccines in the options listed. However, there are no recommendations from ACIP re the recombinant zoster vaccine). Reference: Harrison's, 21st ed., Figure 123- 1..
[Audio] Answer: Influenza: older adult with hypotension because of dengue virus infection. In general, vaccine administration should be deferred in moderate or severe acute illness (with or without fever) until illness resolves to avoid the superimposition of adverse effects of vaccination on the underlying illness and the mistaken attribution to the vaccine. All other options are contraindications. Reference: Harrison's, 21st ed., Table 123- 3 and page 983..
[Audio] Answer: Breastfeeding Administration of live (and non-live) vaccines are recommended in breastfeeding patients who meet age requirements or who have other co-morbid conditions. Reference: Harrison's, 21st ed., page 983..
[Audio] Answer: 1. Although the PPSV can be administered through either the SC or IM route, the latter lowers the risk of injection site reactions. Based on the patient's sex and weight a 1-inch needle should be used for IM administration of the vaccine. Reference: Harrison's, 21st ed., page 986..
[Audio] Answer: Efficacy of vaccines are maintained if he receives the vaccines all at the same visit. dministration of all needed vaccines at one visit is encouraged. Simultaneous administration does not affect immunogenicity of vaccines, nor does it increase the risk of adverse events. Option D is false: vaccine administered on the deltoid may be separated by 1- 2 inches to monitor for local reactions. Also, option A is false because as a non-live vaccine, the recombinant zoster vaccine may be administered at the same time as the live varicella virus vaccine. Reference: Harrison's, 21st ed., page 987.
[Audio] Answer: He may receive it during the last week of October.. As a multi-dose vaccine, the HBV vaccine is administered at 0, 1, 6 months. Giving the vaccine dose too early affects immunogenicity. There is no need to repeat the primary series for this patient because he has yet to receive his 3rd dose which is due on the last week of October this year. Although the number of doses for the HBV vaccine depends on the type of vaccine used, the patient's medical condition may affect immunogenicity and may have to receive more than 3 doses of the HBV vaccine. Reference: ACIP/ CDC; Harrison's 21st ed., page 986 ( administration of vaccines) and Table 123-1.
[Audio] Answer: Both Lymphadenopathy and Fever . All adverse events are reportable. Reference: CDC/ ACIP, Harrison's 21st ed., DOH-PH.
[Audio] Answer: TdaP . Options B-D are recommended if with risk factor-based indications. Reference: Harrisons, 21st ed., Figure 123- 1.
[Audio] Answer: 50 y/ o person with HIV with undetectable viral load. There are certain population considered at high risk for influenza infection and should be given high priority status for influenza immunization. Reference: Harrison's, 21st ed., chap 200/Table 200- 2.
[Audio] Answer: 0, 1, 6 months then one Td for every pregnancy thereafter. A non-immunized pregnant patient should receive 2 doses of Td separated by 4 weeks, then a 3rd dose after 6 months (i.e., 0, 1, 6) then one dose of Td for every pregnancy thereafter up to 5 doses for long term immunity. Reference: Harrison's, 21st ed., chap 152, and PHEX.